永安药业(002365.SZ)拟回购2500万元-5000万元的股份 回购价不超10.00元/股
格隆汇8月24日丨永安药业(002365.SZ)公布,公司拟使用自有资金以集中竞价交易方式回购公司部分股份,回购总金额不低于人民币2500万元(含),不超过人民币5000万元(含);回购价格不超过人民币10.00元/股(含);若全额回购且按回购总金额上限和回购股份价格上限测算,预计可回购股份数量约500万股,回购股份比例约占公司总股本的1.70%,具体回购数量以回购期满时实际回购的股份数量为准;回购股份期限为自董事会审议通过此次回购股份事项之日起不超过12个月;此次回购股份将用于公司员工持股计划或股权激励。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.